A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy

A 73-year-old woman with lung adenocarcinoma (cT4N3M1a: Stage IVA) was treated with atezolizumab as the eighth line of therapy. Four weeks after the fourth dose of atezolizumab, the prothrombin time (PT) and activated thromboplastin time (APTT) were prolonged. Coagulation factor V (FV) activity was...

Full description

Saved in:
Bibliographic Details
Published in:Respirology case reports 2024, Vol.12 (2), p.e01307-e01307
Main Authors: Haruta, Yuki, Azuma, Masanori, Sado, Toshikatsu, Saito, Ryuichi, Miyazaki, Yoshimune, Noda, Akihiro, Kitagawa, Reina, Hori, Yasutaka, Fujimoto, Sayaka, Hasegawa, Yoshinori, Ueda, Tetsuya, Yamamura, Ryosuke
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page e01307
container_issue 2
container_start_page e01307
container_title Respirology case reports
container_volume 12
creator Haruta, Yuki
Azuma, Masanori
Sado, Toshikatsu
Saito, Ryuichi
Miyazaki, Yoshimune
Noda, Akihiro
Kitagawa, Reina
Hori, Yasutaka
Fujimoto, Sayaka
Hasegawa, Yoshinori
Ueda, Tetsuya
Yamamura, Ryosuke
description A 73-year-old woman with lung adenocarcinoma (cT4N3M1a: Stage IVA) was treated with atezolizumab as the eighth line of therapy. Four weeks after the fourth dose of atezolizumab, the prothrombin time (PT) and activated thromboplastin time (APTT) were prolonged. Coagulation factor V (FV) activity was decreased, and FV inhibitors were observed. There was no history of PT or APTT prolongation or bleeding before the use of atezolizumab. Atezolizumab-induced coagulation FV inhibitor was diagnosed. After 2 weeks, the PT and APTT spontaneously normalized. FV activity improved and the FV inhibitors disappeared after 6 and 9 weeks, respectively.
doi_str_mv 10.1002/rcr2.1307
format report
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_2927211093</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2927211093</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_29272110933</originalsourceid><addsrcrecordid>eNqVjr0OAUEURidCQtjCG9xSgzszkaUUIR5AKDdj3LXD7syan8LbI1FoVd_Jl1McxsYcZxxRzL32YsYl5h02ELjgUymX2P3hPstCuCEi5--L8wE7rUGrQOBK0E5dU62icRZKpaPzcARjK3M2Hzb2kjRd4PwE0zTJEuiK9L11xsYfLVbkVfscsV6p6kDZd4dsstseNvtp690jUYhFY4KmulaWXAqFWIlcvKtWUv6hvgBpu0uL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype><pqid>2927211093</pqid></control><display><type>report</type><title>A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy</title><source>Open Access: Wiley-Blackwell Open Access Journals</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Haruta, Yuki ; Azuma, Masanori ; Sado, Toshikatsu ; Saito, Ryuichi ; Miyazaki, Yoshimune ; Noda, Akihiro ; Kitagawa, Reina ; Hori, Yasutaka ; Fujimoto, Sayaka ; Hasegawa, Yoshinori ; Ueda, Tetsuya ; Yamamura, Ryosuke</creator><creatorcontrib>Haruta, Yuki ; Azuma, Masanori ; Sado, Toshikatsu ; Saito, Ryuichi ; Miyazaki, Yoshimune ; Noda, Akihiro ; Kitagawa, Reina ; Hori, Yasutaka ; Fujimoto, Sayaka ; Hasegawa, Yoshinori ; Ueda, Tetsuya ; Yamamura, Ryosuke</creatorcontrib><description>A 73-year-old woman with lung adenocarcinoma (cT4N3M1a: Stage IVA) was treated with atezolizumab as the eighth line of therapy. Four weeks after the fourth dose of atezolizumab, the prothrombin time (PT) and activated thromboplastin time (APTT) were prolonged. Coagulation factor V (FV) activity was decreased, and FV inhibitors were observed. There was no history of PT or APTT prolongation or bleeding before the use of atezolizumab. Atezolizumab-induced coagulation FV inhibitor was diagnosed. After 2 weeks, the PT and APTT spontaneously normalized. FV activity improved and the FV inhibitors disappeared after 6 and 9 weeks, respectively.</description><identifier>ISSN: 2051-3380</identifier><identifier>EISSN: 2051-3380</identifier><identifier>DOI: 10.1002/rcr2.1307</identifier><language>eng</language><ispartof>Respirology case reports, 2024, Vol.12 (2), p.e01307-e01307</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784,4490,27925,37013</link.rule.ids></links><search><creatorcontrib>Haruta, Yuki</creatorcontrib><creatorcontrib>Azuma, Masanori</creatorcontrib><creatorcontrib>Sado, Toshikatsu</creatorcontrib><creatorcontrib>Saito, Ryuichi</creatorcontrib><creatorcontrib>Miyazaki, Yoshimune</creatorcontrib><creatorcontrib>Noda, Akihiro</creatorcontrib><creatorcontrib>Kitagawa, Reina</creatorcontrib><creatorcontrib>Hori, Yasutaka</creatorcontrib><creatorcontrib>Fujimoto, Sayaka</creatorcontrib><creatorcontrib>Hasegawa, Yoshinori</creatorcontrib><creatorcontrib>Ueda, Tetsuya</creatorcontrib><creatorcontrib>Yamamura, Ryosuke</creatorcontrib><title>A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy</title><title>Respirology case reports</title><description>A 73-year-old woman with lung adenocarcinoma (cT4N3M1a: Stage IVA) was treated with atezolizumab as the eighth line of therapy. Four weeks after the fourth dose of atezolizumab, the prothrombin time (PT) and activated thromboplastin time (APTT) were prolonged. Coagulation factor V (FV) activity was decreased, and FV inhibitors were observed. There was no history of PT or APTT prolongation or bleeding before the use of atezolizumab. Atezolizumab-induced coagulation FV inhibitor was diagnosed. After 2 weeks, the PT and APTT spontaneously normalized. FV activity improved and the FV inhibitors disappeared after 6 and 9 weeks, respectively.</description><issn>2051-3380</issn><issn>2051-3380</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2024</creationdate><recordtype>report</recordtype><recordid>eNqVjr0OAUEURidCQtjCG9xSgzszkaUUIR5AKDdj3LXD7syan8LbI1FoVd_Jl1McxsYcZxxRzL32YsYl5h02ELjgUymX2P3hPstCuCEi5--L8wE7rUGrQOBK0E5dU62icRZKpaPzcARjK3M2Hzb2kjRd4PwE0zTJEuiK9L11xsYfLVbkVfscsV6p6kDZd4dsstseNvtp690jUYhFY4KmulaWXAqFWIlcvKtWUv6hvgBpu0uL</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Haruta, Yuki</creator><creator>Azuma, Masanori</creator><creator>Sado, Toshikatsu</creator><creator>Saito, Ryuichi</creator><creator>Miyazaki, Yoshimune</creator><creator>Noda, Akihiro</creator><creator>Kitagawa, Reina</creator><creator>Hori, Yasutaka</creator><creator>Fujimoto, Sayaka</creator><creator>Hasegawa, Yoshinori</creator><creator>Ueda, Tetsuya</creator><creator>Yamamura, Ryosuke</creator><scope>7X8</scope></search><sort><creationdate>20240201</creationdate><title>A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy</title><author>Haruta, Yuki ; Azuma, Masanori ; Sado, Toshikatsu ; Saito, Ryuichi ; Miyazaki, Yoshimune ; Noda, Akihiro ; Kitagawa, Reina ; Hori, Yasutaka ; Fujimoto, Sayaka ; Hasegawa, Yoshinori ; Ueda, Tetsuya ; Yamamura, Ryosuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_29272110933</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Haruta, Yuki</creatorcontrib><creatorcontrib>Azuma, Masanori</creatorcontrib><creatorcontrib>Sado, Toshikatsu</creatorcontrib><creatorcontrib>Saito, Ryuichi</creatorcontrib><creatorcontrib>Miyazaki, Yoshimune</creatorcontrib><creatorcontrib>Noda, Akihiro</creatorcontrib><creatorcontrib>Kitagawa, Reina</creatorcontrib><creatorcontrib>Hori, Yasutaka</creatorcontrib><creatorcontrib>Fujimoto, Sayaka</creatorcontrib><creatorcontrib>Hasegawa, Yoshinori</creatorcontrib><creatorcontrib>Ueda, Tetsuya</creatorcontrib><creatorcontrib>Yamamura, Ryosuke</creatorcontrib><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haruta, Yuki</au><au>Azuma, Masanori</au><au>Sado, Toshikatsu</au><au>Saito, Ryuichi</au><au>Miyazaki, Yoshimune</au><au>Noda, Akihiro</au><au>Kitagawa, Reina</au><au>Hori, Yasutaka</au><au>Fujimoto, Sayaka</au><au>Hasegawa, Yoshinori</au><au>Ueda, Tetsuya</au><au>Yamamura, Ryosuke</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy</atitle><jtitle>Respirology case reports</jtitle><date>2024-02-01</date><risdate>2024</risdate><volume>12</volume><issue>2</issue><spage>e01307</spage><epage>e01307</epage><pages>e01307-e01307</pages><issn>2051-3380</issn><eissn>2051-3380</eissn><abstract>A 73-year-old woman with lung adenocarcinoma (cT4N3M1a: Stage IVA) was treated with atezolizumab as the eighth line of therapy. Four weeks after the fourth dose of atezolizumab, the prothrombin time (PT) and activated thromboplastin time (APTT) were prolonged. Coagulation factor V (FV) activity was decreased, and FV inhibitors were observed. There was no history of PT or APTT prolongation or bleeding before the use of atezolizumab. Atezolizumab-induced coagulation FV inhibitor was diagnosed. After 2 weeks, the PT and APTT spontaneously normalized. FV activity improved and the FV inhibitors disappeared after 6 and 9 weeks, respectively.</abstract><doi>10.1002/rcr2.1307</doi></addata></record>
fulltext fulltext
identifier ISSN: 2051-3380
ispartof Respirology case reports, 2024, Vol.12 (2), p.e01307-e01307
issn 2051-3380
2051-3380
language eng
recordid cdi_proquest_miscellaneous_2927211093
source Open Access: Wiley-Blackwell Open Access Journals; Publicly Available Content Database; PubMed Central
title A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A40%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=A%20case%20of%20coagulation%20factor%20V%20inhibitor%20induced%20by%20immune%20checkpoint%20inhibitor%20therapy&rft.jtitle=Respirology%20case%20reports&rft.au=Haruta,%20Yuki&rft.date=2024-02-01&rft.volume=12&rft.issue=2&rft.spage=e01307&rft.epage=e01307&rft.pages=e01307-e01307&rft.issn=2051-3380&rft.eissn=2051-3380&rft_id=info:doi/10.1002/rcr2.1307&rft_dat=%3Cproquest%3E2927211093%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_29272110933%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2927211093&rft_id=info:pmid/&rfr_iscdi=true